This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis (DIRECT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo Inc. ( Daiichi Sankyo Co., Ltd. )
ClinicalTrials.gov Identifier:
NCT00680953
First received: May 16, 2008
Last updated: February 19, 2015
Last verified: February 2015
May 16, 2008
February 19, 2015
May 2008
June 2012   (Final data collection date for primary outcome measure)
Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo [ Time Frame: Baseline to 24 months ]
  • Reduction of the incident rate of fragilty vertebral fractures with denosumab compared to placebo [ Time Frame: 24 Months ]
  • Safety profile of denosumab [ Time Frame: 24 Months ]
Complete list of historical versions of study NCT00680953 on ClinicalTrials.gov Archive Site
  • The Percentage of Non-vertebral Fractures [ Time Frame: Baseline to 24 Months ]
    The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures
  • Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo. [ Time Frame: Baseline to 24 Months ]
    The results are expressed as a percentage by Kaplan-Meier estimate.
  • Incident rate on non-vertebral fractures [ Time Frame: 24 Months ]
  • Incident rate of hip fractures [ Time Frame: 24 Months ]
  • Assessment of adverse events and laboratory test changes from baseline [ Time Frame: 24 months and 36 months ]
Not Provided
Not Provided
 
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)
Evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Osteoporosis
  • Drug: Denosumab
    Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
  • Drug: Placebo
    Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
  • Drug: Alendronate sodium hydrate
    Oral tablet once a week for 24 months
  • Experimental: 1
    Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
    Intervention: Drug: Denosumab
  • Placebo Comparator: 2
    Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
    Intervention: Drug: Placebo
  • Active Comparator: 3
    Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).
    Intervention: Drug: Alendronate sodium hydrate

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1262
July 2012
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Involutional (postmenopausal and senile) osteoporosis with prevalent fragility vertebral fractures

Exclusion Criteria:

  • Any underlying condition,(other than BMD) that might have resulted in abnormal bone metabolism
Sexes Eligible for Study: All
50 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00680953
AMG162-A-J301
Yes
Not Provided
Not Provided
Not Provided
Daiichi Sankyo Inc. ( Daiichi Sankyo Co., Ltd. )
Daiichi Sankyo Co., Ltd.
Not Provided
Study Chair: Daiichi Sankyo R&D Division, Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Inc.
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP